Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15105841 | 0.79 | DGAT1 (0.50) | DGAT1PKM | |
| SCHEMBL756999 | 0.76 | EPHX1 (0.36) | PKMALDH1A1 | |
| SCHEMBL4763650 | 0.74 | — | — | |
| SCHEMBL8173647 | 0.72 | — | — | |
| SCHEMBL412680 | 0.72 | — | — | |
| SCHEMBL13179066 | 0.71 | DGAT1 (0.46) | DGAT1KCNN4ALDH1A1SRC | |
| SCHEMBL9086982 | 0.71 | TSHR (0.42) | ALDH1A1 | |
| SCHEMBL24101210 | 0.70 | DGAT1 (0.41) | DGAT1CNR2KCNN4ALDH1A1 | |
| SCHEMBL12563721 | 0.70 | ELANE (0.43) | DGAT1PKMCNR2KCNN4ALDH1A1 | |
| SCHEMBL1424791 | 0.69 | DGAT1 (0.50) | DGAT1KCNN4ALDH1A1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-6841703-B2 | Open chain alkoxyamine compounds and their use as polymerization regulators | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1100772-B1 | OPEN CHAIN ALKOXYAMINE COMPOUNDS AND THEIR USE AS POLYMERIZATION REGULATORS | CIBA SC HOLDING AG (CH) | 2004-04-14 | — | — | EP | disclosed |
| US-20030125489-A1 | Open chain alkoxyamine compounds and their use as polymerization regulators | NESVADBA PETER (CH) | 2003-07-03 | — | — | US | disclosed |
| US-6518326-B1 | Open chain alkoxyamine compounds and their use as polymerization regulators | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1100772-A1 | OPEN CHAIN ALKOXYAMINE COMPOUNDS AND THEIR USE AS POLYMERIZATION REGULATORS | Ciba SC Holding AG (CH) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000007981-A1 | OPEN CHAIN ALKOXYAMINE COMPOUNDS AND THEIR USE AS POLYMERIZATION REGULATORS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | DGAT1 1/4885PKM 1434/4885CNR2 1926/4885 |
| US-20030125489-A1 | Open chain alkoxyamine compounds and their use as polymerization regulators | ALOX5, PTGER1, ALOX12 | DGAT1 233/4885PKM 2631/4885CNR2 1177/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | DGAT1 1/4885PKM 1282/4885CNR2 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.